204 related articles for article (PubMed ID: 35221589)
1. Principal Component Analysis to Differentiate Patients with Palmoplantar Pustulosis from Those with Palmoplantar Pustular Psoriasis.
Kim TH; Kim JS; Kwon JE; Park B; Lee ES
Ann Dermatol; 2022 Feb; 34(1):7-13. PubMed ID: 35221589
[TBL] [Abstract][Full Text] [Related]
2. Based on Molecular Profiling of Gene Expression, Palmoplantar Pustulosis and Palmoplantar Pustular Psoriasis Are Highly Related Diseases that Appear to Be Distinct from Psoriasis Vulgaris.
Bissonnette R; Suárez-Fariñas M; Li X; Bonifacio KM; Brodmerkel C; Fuentes-Duculan J; Krueger JG
PLoS One; 2016; 11(5):e0155215. PubMed ID: 27152848
[TBL] [Abstract][Full Text] [Related]
3. Vesicular LL-37 contributes to inflammation of the lesional skin of palmoplantar pustulosis.
Murakami M; Kaneko T; Nakatsuji T; Kameda K; Okazaki H; Dai X; Hanakawa Y; Tohyama M; Ishida-Yamamoto A; Sayama K
PLoS One; 2014; 9(10):e110677. PubMed ID: 25330301
[TBL] [Abstract][Full Text] [Related]
4. The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.
Sanchez IM; Sorenson E; Levin E; Liao W
Dermatol Ther (Heidelb); 2017 Dec; 7(4):425-446. PubMed ID: 29143230
[TBL] [Abstract][Full Text] [Related]
5. Biologic therapies associated with development of palmoplantar pustulosis and palmoplantar pustular psoriasis: a systematic review.
Lu JD; Lytvyn Y; Mufti A; Zaaroura H; Sachdeva M; Kwan S; Abduelmula A; Kim P; Yeung J
Int J Dermatol; 2023 Jan; 62(1):12-21. PubMed ID: 35128653
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in palmoplantar pustulosis.
Brunasso AMG; Massone C
Fac Rev; 2021; 10():62. PubMed ID: 34409425
[TBL] [Abstract][Full Text] [Related]
7. Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options.
Menter A; Van Voorhees AS; Hsu S
Dermatol Ther (Heidelb); 2021 Dec; 11(6):1917-1929. PubMed ID: 34626330
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial.
Bissonnette R; Nigen S; Langley RG; Lynde CW; Tan J; Fuentes-Duculan J; Krueger JG
J Eur Acad Dermatol Venereol; 2014 Oct; 28(10):1298-305. PubMed ID: 24112799
[TBL] [Abstract][Full Text] [Related]
9. Palmoplantar pustulosis: Current understanding of disease definition and pathomechanism.
Murakami M; Terui T
J Dermatol Sci; 2020 Apr; 98(1):13-19. PubMed ID: 32201085
[TBL] [Abstract][Full Text] [Related]
10. Increased levels of lipocalin 2 in palmoplantar pustular psoriasis.
Wolk K; Frambach Y; Jacobi A; Wilsmann-Theis D; Phillipp S; Witte-Händel E; Wenzel J; Mössner R; Sabat R
J Dermatol Sci; 2018 Apr; 90(1):68-74. PubMed ID: 29395573
[TBL] [Abstract][Full Text] [Related]
11. Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis.
Baum P; Visvanathan S; Garcet S; Roy J; Schmid R; Bossert S; Lang B; Bachelez H; Bissonnette R; Thoma C; Krueger JG
J Allergy Clin Immunol; 2022 Apr; 149(4):1402-1412. PubMed ID: 34678325
[TBL] [Abstract][Full Text] [Related]
12. Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway.
Bissonnette R; Fuentes-Duculan J; Mashiko S; Li X; Bonifacio KM; Cueto I; Suárez-Fariñas M; Maari C; Bolduc C; Nigen S; Sarfati M; Krueger JG
J Dermatol Sci; 2017 Jan; 85(1):20-26. PubMed ID: 27743912
[TBL] [Abstract][Full Text] [Related]
13. Similarity and difference between palmoplantar pustulosis and pustular psoriasis.
Yamamoto T
J Dermatol; 2021 Jun; 48(6):750-760. PubMed ID: 33650702
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and Burdens of Disease in Patients from Beijing with Generalized Pustular Psoriasis and Palmoplantar Pustulosis: Multicenter Retrospective Cohort Study Using a Regional Database.
Wang HM; Xu JM; Jin HZ
Am J Clin Dermatol; 2023 Nov; 24(6):991-1002. PubMed ID: 37386353
[TBL] [Abstract][Full Text] [Related]
15. Clinical and epidemiological comparison of patients affected by palmoplantar plaque psoriasis and palmoplantar pustulosis: a case series study.
Brunasso AM; Puntoni M; Aberer W; Delfino C; Fancelli L; Massone C
Br J Dermatol; 2013 Jun; 168(6):1243-51. PubMed ID: 23301847
[TBL] [Abstract][Full Text] [Related]
16. DiGeorge syndrome presenting with palmoplantar pustules: Comparative analysis of serum IL-22, NETs and IL-8 with usual palmoplantar pustulosis.
Ogura Y; Kondo S; Suzuki T; Otsuka M; Inuzuka M; Honda T; Tokura Y
J Dermatol; 2024 May; 51(5):731-734. PubMed ID: 38111339
[TBL] [Abstract][Full Text] [Related]
17. Interleukin (IL)-8 and IL-36γ but not IL-36Ra are related to acrosyringia in pustule formation associated with palmoplantar pustulosis.
Xiaoling Y; Chao W; Wenming W; Feng L; Hongzhong J
Clin Exp Dermatol; 2019 Jan; 44(1):52-57. PubMed ID: 29896852
[TBL] [Abstract][Full Text] [Related]
18. HL-A antigens in patients with persistent palmoplantar pustulosis and pustular psoriasis.
Karvonen J; Tiilikainen A; Lassus A
Ann Clin Res; 1975 Apr; 7(2):112-5. PubMed ID: 1181975
[TBL] [Abstract][Full Text] [Related]
19. A brief guide to pustular psoriasis for primary care providers.
Crowley JJ; Pariser DM; Yamauchi PS
Postgrad Med; 2021 Apr; 133(3):330-344. PubMed ID: 33118424
[TBL] [Abstract][Full Text] [Related]
20. Six-transmembrane epithelial antigens of the prostate comprise a novel inflammatory nexus in patients with pustular skin disorders.
Liang Y; Xing X; Beamer MA; Swindell WR; Sarkar MK; Roberts LW; Voorhees JJ; Kahlenberg JM; Harms PW; Johnston A; Gudjonsson JE
J Allergy Clin Immunol; 2017 Apr; 139(4):1217-1227. PubMed ID: 27884600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
